ArticleJournal of Cancer2026
Clinical Outcomes and Individualized Seed Implantation Planning for Iodine-125 Seeds Brachytherapy in Lymph Node Metastases.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node metastasis (LNM) critically influences cancer prognosis and treatment. This study explored the efficacy and prognostic factors of CT-guided radioactive iodine-125 (¹²⁵I) seed brachytherapy (RISB) for LNM and optimized the therapeutic dosage. Methods: We conducted a single-center retrospective cohort study analyzing 81 cases with histologically confirmed LNM (≤ 5 cm) from diverse primary cancers treated with CT-guided RISB. Postoperative dosimetric parameters (D90, D100, V90, V100, V150, V200) were assessed. Treatment response was evaluated at 6 months using RECIST 1.1, calculating the objective response rate (ORR) and local control rate (LCR). Patients were categorized into objective response and non-objective response groups based on treatment efficacy, and factors influencing treatment efficacy were identified through logistic regression analysis. Based on the ROC curve, the Youden index method was used to determine the dose optimization cutoff value. Results: The overall ORR was 71.6%, and LCR was 96.3%. The complication rate was 3.7%. Tumor size was an independent influencing factor for efficacy. Higher postoperative dosimetric parameters were associated with efficacy but were not independent influencing factors. ROC analysis identified the optimal D90 threshold as 102.7 Gy. The ORR in patients who achieved D90 > 102.7 Gy (n = 65, ORR = 81.54%) was significantly higher than in patients with D90 ≤ 102.7 Gy (n = 16, ORR = 31.25%) (p < 0.01). Complication rates did not differ between dose groups. Conclusion: Patients with LNM undergoing RISB can achieve a significantly higher ORR by ensuring a postoperative D90 > 102.7 Gy, without increasing the risk of complications. This dose threshold serves as a practical reference for clinical dose planning. Tumor size independently influences better response, guiding patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.